These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 21187590

  • 1. [Therapeutic agents for disorders of bone and calcium metabolism: Weekly subcutaneous injection of teriparatide.].
    Ishizuya T.
    Clin Calcium; 2011 Jan; 21(1):17-24. PubMed ID: 21187590
    [Abstract] [Full Text] [Related]

  • 2. [Therapeutic agents for disorders of bone and calcium metabolism--Parathyroid hormone in weekly subcutaneous injection].
    Uzawa T.
    Clin Calcium; 2007 Jan; 17(1):56-62. PubMed ID: 17211094
    [Abstract] [Full Text] [Related]

  • 3. [Teriparatide: human recombinant parathyroid hormone (1-34) as a daily subcutaneous injection].
    Sowa H, Hamaya E, Yamamoto T.
    Clin Calcium; 2011 Jan; 21(1):9-16. PubMed ID: 21187589
    [Abstract] [Full Text] [Related]

  • 4. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
    Hashimoto Y, Wakayama N, Miyauchi A.
    Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
    [Abstract] [Full Text] [Related]

  • 5. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
    Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E.
    Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
    [Abstract] [Full Text] [Related]

  • 6. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y.
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [Abstract] [Full Text] [Related]

  • 7. [Evidence for osteoporosis treatment using PTH (1-34) daily subcutaneous injection].
    Yamamoto T, Hamaya E, Sowa H.
    Clin Calcium; 2012 Mar; 22(3):399-406. PubMed ID: 22370307
    [Abstract] [Full Text] [Related]

  • 8. [Effects of parathyroid hormone (teriparatide) on bone quality in osteoporosis].
    Saito M, Marumo K.
    Clin Calcium; 2012 Mar; 22(3):343-55. PubMed ID: 22370301
    [Abstract] [Full Text] [Related]

  • 9. [Therapeutic agents for disorders of bone and calcium metabolism. Development of nasal formulation of hPTH (1-34)].
    Sato K.
    Clin Calcium; 2007 Jan; 17(1):64-71. PubMed ID: 17211095
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E.
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [Abstract] [Full Text] [Related]

  • 12. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 13. [Once-weekly teriparatide treatment on osteoporosis].
    Nakano T.
    Clin Calcium; 2014 Jan 10; 24(1):100-5. PubMed ID: 24369286
    [Abstract] [Full Text] [Related]

  • 14. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
    Marumo K, Saito M.
    Nihon Rinsho; 2011 Jul 10; 69(7):1264-9. PubMed ID: 21774369
    [Abstract] [Full Text] [Related]

  • 15. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep 10; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 16. [Monitoring bone turnover markers during treatment with the anabolic agent teriparatide; in particular, treatment using daily and weekly subucutaneous injections].
    Miyauchi A.
    Clin Calcium; 2012 Mar 10; 22(3):387-98. PubMed ID: 22370306
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun 10; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 18. [Daily subcutaneous injection of teriparatide : the progress and current issues].
    Yano S, Sugimoto T.
    Clin Calcium; 2014 Jan 10; 24(1):35-43. PubMed ID: 24369278
    [Abstract] [Full Text] [Related]

  • 19. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun 10; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 20. [Update and perspectives of anabolic therapies for osteoporosis].
    Endo I, Matsumoto T.
    Clin Calcium; 2012 Mar 10; 22(3):327-33. PubMed ID: 22370299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.